Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2020 - 2025)

Insight Molecular Diagnostics' Other Operating Expenses history spans 6 years, with the latest figure at $4.8 million for Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 41.78% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $40.5 million, up 68.16%, while the annual FY2024 figure was $41.7 million, 722.75% up from the prior year.
  • Other Operating Expenses for Q3 2025 was $4.8 million at Insight Molecular Diagnostics, up from $4.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $29.4 million in Q4 2024 and bottomed at -$11.4 million in Q1 2023.
  • The 5-year median for Other Operating Expenses is $3.3 million (2021), against an average of $3.8 million.
  • The largest annual shift saw Other Operating Expenses tumbled 446.36% in 2022 before it skyrocketed 2495.51% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $17.7 million in 2021, then plummeted by 70.8% to $5.2 million in 2022, then surged by 128.14% to $11.8 million in 2023, then soared by 149.99% to $29.4 million in 2024, then plummeted by 83.8% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other Operating Expenses are $4.8 million (Q3 2025), $4.3 million (Q2 2025), and $2.1 million (Q1 2025).